These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. Activation or inactivation of cardiac Akt/mTOR signaling diverges physiological from pathological hypertrophy. Kemi OJ; Ceci M; Wisloff U; Grimaldi S; Gallo P; Smith GL; Condorelli G; Ellingsen O J Cell Physiol; 2008 Feb; 214(2):316-21. PubMed ID: 17941081 [TBL] [Abstract][Full Text] [Related]
8. FoxO1 is required for physiological cardiac hypertrophy induced by exercise but not by constitutively active PI3K. Weeks KL; Tham YK; Yildiz SG; Alexander Y; Donner DG; Kiriazis H; Harmawan CA; Hsu A; Bernardo BC; Matsumoto A; DePinho RA; Abel ED; Woodcock EA; McMullen JR Am J Physiol Heart Circ Physiol; 2021 Apr; 320(4):H1470-H1485. PubMed ID: 33577435 [TBL] [Abstract][Full Text] [Related]
9. Insulin-like growth factor I receptor signaling is required for exercise-induced cardiac hypertrophy. Kim J; Wende AR; Sena S; Theobald HA; Soto J; Sloan C; Wayment BE; Litwin SE; Holzenberger M; LeRoith D; Abel ED Mol Endocrinol; 2008 Nov; 22(11):2531-43. PubMed ID: 18801929 [TBL] [Abstract][Full Text] [Related]
10. IGF1-PI3K-induced physiological cardiac hypertrophy: Implications for new heart failure therapies, biomarkers, and predicting cardiotoxicity. Bass-Stringer S; Tai CMK; McMullen JR J Sport Health Sci; 2021 Dec; 10(6):637-647. PubMed ID: 33246162 [TBL] [Abstract][Full Text] [Related]
11. Pik3ip1 modulates cardiac hypertrophy by inhibiting PI3K pathway. Song HK; Kim J; Lee JS; Nho KJ; Jeong HC; Kim J; Ahn Y; Park WJ; Kim DH PLoS One; 2015; 10(3):e0122251. PubMed ID: 25826393 [TBL] [Abstract][Full Text] [Related]
12. Deletion of ribosomal S6 kinases does not attenuate pathological, physiological, or insulin-like growth factor 1 receptor-phosphoinositide 3-kinase-induced cardiac hypertrophy. McMullen JR; Shioi T; Zhang L; Tarnavski O; Sherwood MC; Dorfman AL; Longnus S; Pende M; Martin KA; Blenis J; Thomas G; Izumo S Mol Cell Biol; 2004 Jul; 24(14):6231-40. PubMed ID: 15226426 [TBL] [Abstract][Full Text] [Related]
14. Bcl-2 Is Involved in Cardiac Hypertrophy through PI3K-Akt Pathway. Meng X; Cui J; He G Biomed Res Int; 2021; 2021():6615502. PubMed ID: 33778070 [TBL] [Abstract][Full Text] [Related]
15. (-)-Epicatechin induces physiological cardiac growth by activation of the PI3K/Akt pathway in mice. De Los Santos S; García-Pérez V; Hernández-Reséndiz S; Palma-Flores C; González-Gutiérrez CJ; Zazueta C; Canto P; Coral-Vázquez RM Mol Nutr Food Res; 2017 Feb; 61(2):. PubMed ID: 27605464 [TBL] [Abstract][Full Text] [Related]
16. Molecular distinction between physiological and pathological cardiac hypertrophy: experimental findings and therapeutic strategies. Bernardo BC; Weeks KL; Pretorius L; McMullen JR Pharmacol Ther; 2010 Oct; 128(1):191-227. PubMed ID: 20438756 [TBL] [Abstract][Full Text] [Related]
17. Signaling through PI3K/Akt mediates stretch and PDGF-BB-dependent DNA synthesis in bladder smooth muscle cells. Adam RM; Roth JA; Cheng HL; Rice DC; Khoury J; Bauer SB; Peters CA; Freeman MR J Urol; 2003 Jun; 169(6):2388-93. PubMed ID: 12771803 [TBL] [Abstract][Full Text] [Related]
18. The therapeutic potential of miRNAs regulated in settings of physiological cardiac hypertrophy. Ooi JY; Bernardo BC; McMullen JR Future Med Chem; 2014 Feb; 6(2):205-22. PubMed ID: 24467244 [TBL] [Abstract][Full Text] [Related]
19. Clusterin is regulated by IGF1-PI3K signaling in the heart: implications for biomarker and drug target discovery, and cardiotoxicity. Bass-Stringer S; Ooi JYY; McMullen JR Arch Toxicol; 2020 May; 94(5):1763-1768. PubMed ID: 32172307 [TBL] [Abstract][Full Text] [Related]
20. The PI3K/Akt/mTOR signaling pathway mediates insulin-like growth factor 1-induced E-cadherin down-regulation and cell proliferation in ovarian cancer cells. Lau MT; Leung PC Cancer Lett; 2012 Dec; 326(2):191-8. PubMed ID: 22922215 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]